The first attempt to win government approval of a psychedelic drug for mental health treatment is generating skepticism about its clinical trials. A recent independent analysis questioned the integrity of patient studies that are being used to support the Food and Drug Administration application for MDMA to treat post-traumatic stress disorder. In other words, the trial was not “blinded” for purposes of comparing the drug’s effect, which undermines the results.